CytomX Therapeutics, Inc. (CTMX)

Market Cap	178.43M
Revenue (ttm)	71.94M
Net Income (ttm)	-97.59M
Shares Out	66.08M
EPS (ttm)	-1.49
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	924,723
Open	2.63
Previous Close	2.68
Day's Range	2.63 - 2.74
52-Week Range	1.17 - 4.73
Beta	0.40
Analysts	Hold
Price Target	2.88 (+6.67%)
Earnings Date	Feb 27, 2023

About CTMX

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gas...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 8, 2015
• Employees: 174
• Stock Exchange: NASDAQ
• Ticker Symbol: CTMX

Financial Performance

In 2021, CTMX's revenue was $69.57 million, a decrease of -30.68% compared to the previous year's $100.36 million. Losses were -$83.61 million, 154.2% more than in 2020.

Analyst Forecast

According to 14 analysts, the average rating for CTMX stock is "Hold." The 12-month stock price forecast is $2.88, which is an increase of 6.67% from the latest price.

Price Target

$2.88

(6.67% upside)

Analyst Consensus: Hold